Taxol, a highly functionalized diterpenoid, is an important antitumor
drug isolated from the Western Yew, Taxus brevifolia, and other Taxus
species. The supply of this drug from natural sources is very limited.
Any attempt to improve the biological production of taxol requires an
understanding of the biosynthesis of this natural product and of the
regulation of the pathway. A biogenetic scheme has been proposed based
on the occurrence of defined taxane metabolites and on analogy to
biosynthetic transformations of simpler monoterpenoids; however, there is
at present no experimentally supported information on the biosynthesis of
taxol. The objective of this project is to determine the number, types
and sequence of enzymatic steps in the transformation of the C20
isoprenoid branch-point intermediate, geranylgeranyl pyrophosphate, to
taxol, and to determine the rate limiting step(s) of the pathway.
Specific aims include: (1) defining the cyclization step of
geranylgeranyl pyrophosphate and the identity of the olefin precursor of
taxol; (2) establishing the sequence of hydroxylations of the parent
olefin on route to taxol, and deciphering the sequence of acetylations of
the hydroxyl groups and the possible biosynthetic function of the
acetylation process; (3) elucidating the enzymatic route of oxetane ring
formation; (4) determining the order and mechanism of late stage
acylations at C-2 and C-13 of the taxol nucleus; and (5) confirming the
pathway by in vivo studies and delineating the rate limiting step(s) of
the pathway. This goal of describing the complex pathway to taxol will
be accomplished through the use of cell-free enzyme systems from T.
brevifolia and the use of radiolabeled precursors. Radiolabeled products
from the early enzymatic reactions will be employed to direct the
isolation and identification of the corresponding intermediates from
Taxus extracts, from which labeled substrates for succeeding enzymatic
transformations will be prepared. In vivo studies employing 14CO2
labeling in intact saplings will then be used to confirm the pathway and,
in combination with isotopic dilution analysis, to determine the rate
limiting step(s). The rate limiting catalyst, and other enzymes of the
pathway relevant to semi-synthetic efforts to produce taxol from more
readily available taxane metabolites, will be the focus of more detailed
study as the foundation for genetic and molecular approaches to the
improved in vivo or in vitro production of the target compound.
No Sub Projects information available for 5R01CA055254-05
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01CA055254-05
Patents
No Patents information available for 5R01CA055254-05
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01CA055254-05
Clinical Studies
No Clinical Studies information available for 5R01CA055254-05
News and More
Related News Releases
No news release information available for 5R01CA055254-05
History
No Historical information available for 5R01CA055254-05
Similar Projects
No Similar Projects information available for 5R01CA055254-05